William Blair Starts Adamas Pharmaceuticals (ADMS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Credit Suisse Starts Adamas Pharmaceuticals (ADMS) at Outperform
May 5, 2014 7:31 AM EDTCredit Suisse initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
... MorePiper Jaffray Starts Adamas Pharmaceuticals (ADMS) at Overweight
May 5, 2014 7:11 AM EDTPiper Jaffray initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Overweight rating and a price target of $32.00.
Analyst David Amsellem comments, "Adamas has the potential to generate compelling cash flows over the long-term, driven by ADS-5102, an extended release (ER) form of amantadine for... More
Needham & Company Starts Adamas Pharmaceuticals (ADMS) at Buy
May 5, 2014 6:21 AM EDTNeedham & Company initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Buy rating and a price target of $33.00.
Analyst Elliot Wilbur comments, "We are initiating coverage of Adamas Pharmaceuticals, a specialty pharma play with a validated platform for developing and commercializing pharmacokinetically enhanced... More
